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Abstract
Background: Gastrointestinal involvement is one of the most serious in Behçet disease, potentially leading to severe
complications. Aim of this study was to investigate at mucosal level the T-cell responses in Behçet patients with early intestinal
involvement.
Methods:We isolated T cells from intestinal mucosa of 8 patients with intestinal symptoms started within 6 months. T lymphocytes
were cloned and analyzed for surface phenotype and cytokines production.
Results:We obtained 382 T-cell clones: 324were CD4+ and 58were CD8+.Within the 324 CD4+ clones, 195were able to secrete
IFN-g and TNF-a, but not IL-4, nor IL-17 thus showing a polarized Th1 profile, whereas CD4 clones producing both IFN-g and IL-17
(Th1/Th17 profile) were 79. Likewise, the number of CD8 clones producing type 1 cytokines was higher than those of CD8 clones
producing both type 1 and 2 cytokines.
Almost all intestinal-derived T-cell clones expressed perforin-mediated cytotoxicity and Fas–Fas Ligand-mediated pro-apoptotic
activity.
Conclusions: Our results indicate that in the early stages of the disease, both Th1 and Th17 cells drive inflammation leading to
mucosal damage via abnormal and long-lasting cytokines production as well as via both perforin- and Fas–Fas ligand-mediated
cytotoxicity. Finally, all the T cells at mucosal level were able to produce large amount of TNF-a, suggesting that its production is a
property of intestinal T cells of patients with early active intestinal disease. These results support the therapy with anti-TNF-a agents
and suggest the use of anti-IL-17 monoclonal antibodies in Behçet patients with early intestinal involvement.
Abbreviations: BD = Behçet disease, IL = interleukin, Th = T helper, Treg = T regulatory.
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11. Introduction
Behçet disease (BD) is a systemic vasculitis characterized by
mucocutaneous, ocular, and articular manifestations, as well as
central nervous system, vascular, and gastrointestinal involve-
ment. BD is common in the Middle East, Mediterranean
countries, and Asia, while it is quite rare in the United States
and Northern European countries.[1] The exact cause of the
disease remains unknown, but it is believed that genetic,
immunological, and environmental factors contribute to its
development.[2] Recently, we have demonstrated that Behçet
patients have a specific gut “microbiome signature.”[3]
T helper (Th) cells are considered the main effectors of adaptive
immunity.[4] T cells are able to differentiate into a Th1 profile in
the presence of large amounts of interleukin (IL)-12 or into Th2 in
the presence of high concentrations of IL-4.[5] Recently other
distinct classes of Th cells have been discovered, such as Th17
lymphocytes. Interestingly, Th17 and T regulatory (Treg) cells
display the highest plasticity to switch to each other, and their
balance seems to be of key importance to determine the
progression or the cessation of autoimmune processes.[4]
T cells have a pathogenetic role also in BD; indeed recent works
have shown an increased production of both Th1 and Th17
cytokines in peripheral blood, skin, and cerebrospinal fluid of
Behçet patients.[6–9] Moreover, it has been observed that anti-
TNF-a treatment, and in particular the chimeric monoclonal
Emmi et al. Medicine (2016) 95:49 Medicineantibody infliximab, is able to increase the proportion of Tregs,
while inhibiting the differentiation of Th17 cells in Behçet
patients with uveitis.[10,11] Interestingly, Kim et al[12] have
recently observed that IL-17A, IL-23R, and STAT4 polymor-
phisms could be involved in the pathogenesis of intestinal
involvement in Behçet patients, almost in the Korean population.
To the best of our knowledge only 2 distinct papers have
investigated the involvement of Th cells in the gut of Behçet
patients, resulting in the evidence of a Th1-polarized re-
sponse.[13,14] Many patients with BD have intestinal symptoms
(mainly diarrhea and abdominal pain), sometimes in the absence
of specific colonoscopy findings; in the 5 nationwide surveys
published in the past years on BD, gastrointestinal involvement
ranges from 7.3% reported in Korean population to 16%
described in Japan.[15] In our country (Italy), the intestinal
involvement is reported in about one third of patients, in
accordance with our patients population.[16] Notably, at the
present time nothing is known about T cells infiltrating the
intestinal mucosa of Behçet patients in the early stages of gut
involvement.
On the basis of these considerations, we speculated that Th17
cells, together with Th1, are involved in the pathogenesis of the
disease and investigated at mucosal level the type, role, and the
cytotoxic potential of T-cell responses in BD with early
gastrointestinal involvement, togather evidence for new biologi-
cal treatments.
2. Material and methods
2.1. Patients enrollment and blood sample collection
From May 2012 to November 2014 8 consecutive patients with
BD who attended the Florence Behçet Center (2 males and 6
females) and 10 healthy controls were included in the study.
Patients with other autoimmune/autoinflammatory disorders,
active infections, neoplasms, or Behçet patients on immunosup-
pressive treatment were excluded from the study. All the patients
complained intestinal symptoms (abdominal pain and diarrhea)
started within 6 months. The ileum bioptic specimens were
collected from patients on treatment with prednisone <10mg/
day and colchicine <2mg/day. The biopsies were performed at
the level of ulcers/aphtous lesions if present (3 patients), or at
ileum level in absence of macroscopic lesions (5 patients). All the
8 patients with BD had evidence at histology of lymphomono-
nuclear and neutrophilic inflammation at the site of ileal biopsies.
None of these patients were under immunosuppressive or
biological drugs at the time of biopsy. All the patients were
diagnosed as having BD according to International Criteria for
Behçet Disease.[17] The study protocol was approved by local
Ethical Committee, and informed consent was obtained from all
subjects enrolled.
2.2. Generation of intestinal T-cell clones
Biopsy specimens were cultured for 7 days in RPMI 1640
medium supplemented with human IL-2 (50U/mL; Eurocetus,
Milan, Italy) to expand in vivo-activated T cells.[18] Mucosal
specimens were then disrupted, and single T-cell blasts were
cloned under limiting dilution (0.3cells/well), as described
previously.[19] The probability for each positive well being a
clone derived from a single precursor was calculated by means of
a conditional probability argument assuming Poisson statis-
tics.[20] The repertoire of the TCR Vb chain of T-cell clones was
analyzed with a panel of 22 mAbs specific to the following: Vb1,2Vb2, Vb4, Vb7, Vb9, Vb11, Vb14, Vb16, Vb18, Vb20,
Vb21.3, Vb22, and Vb23 (Beckman Coulter); and Vb3.1,
Vb5.1, Vb5.2, Vb5.3, Vb6.7, Vb8, Vb12, Vb13, and Vb17
(AMS Biotechnology GmbH). Isotype-matched nonspecific Ig
was used as negative control. Data acquisition was performed in
a FACSCaliburTM flow cytometer using the CELLQuestTM
software program (Becton Dickinson). From each T cell clone,
mRNA was extracted by mRNA direct isolation kit (QIAGEN).
For cDNA synthesis, the same amount of mRNA (50ng) was
used, and cDNA was synthesized by Moloney murine leukemia
virus-reverse transcriptase (New England Biolabs, Inc.) and
oligo-(dT) primers according to the manufacturer’s protocol.
cDNA mix of all samples was amplified under equal conditions
by a 30-cycle PCR using Vb T cell receptor typing amplimer kit
(CLONTECH Laboratories, Inc.) according to the manufac-
turer’s instructions. Evidence for clonality of the T cell clones was
provided by the unique products of PCR analysis of TCR-Vb
mRNA expression obtained in clones or by the cytofluorimetric
patterns of single TCR-Vb expression shown by those clones.
Each T cell clone was stained by only one of the TCR-Vb chain-
specific monoclonal antibodies, showing a single peak of
fluorescence intensity. T-cell clones were analyzed by immuno-
fluorescence on a fluorescence-activated cell-sorter after staining
with the following: fluorescein isothiocyanate, phycoeritrin, or
peridinin chlorophyll protein-conjugated mouse monoclonal
antibodies (anti-CD4, anti-CD8, anti-CD69 purchased from
Becton Dickinson, San Jose, CA). Virtually all T-cell clones
showed individual patterns of response to superantigens (4
staphylococcal enterotoxins: SEA, SEB, SED, and SEE in the
presence of allogeneic APCs), suggesting a difference in their T
cell-reactive Vb-chain expression.2.3. Cytokine profile of intestinal T-cell clones
To assess the cytokines production, 106 T-cell blasts of each clone
were stimulated in duplicate cultures after stimulation for 36
hours with anti-CD3 monoclonal antibody or with PMA plus
anti-CD3monoclonal antibody. Cell-free supernatants were
collected and assayed for their cytokine content (IFN-g, IL-4,
IL-17, and tumor necrosis factor-a; Bio-Source International,
Camarillo, CA) as previously described.[21] Supernatants show-
ing IFN-g, IL-4, IL-17, and TNF-a levels 5 SD over the mean
levels in control supernatants derived from irradiated feeder cells
alone were regarded as positive. T-cell clones able to produce
IFN-g but not IL-4, nor IL-17 were categorized as Th1; clones
able to produce IL-4 but not IFN-g, nor IL-17 as Th2; clones
producing IL-17, but not IFN-g nor IL-4 as Th17; clones
producing both IFN-g and IL-17, but not IL-4 as Th17/Th1; and
clones producing both IFN-g and IL-4, but not IL-17 as Th0, as
previously described.[22]2.4. Perforin-mediated cytolytic activity
Perforin-mediated cytolytic activity of T-cell clones was assessed
as previously reported.[22] The ability of T-cell clones to express
perforin-mediated cytotoxicity was investigated in a lectin-
dependent assay against 51Cr-labeled P815 murine mastocytoma
cells at effector-to-target ratios of 10, 5, and 2.5 to 1 in the
presence of phytohemagglutinin (1% vol/vol), as previously
described.[22] After centrifugation to favor cell-to-cell contact,
microplates were incubated for 8hours at 37 °C, and 0.1mL of
supernatant was removed for the measurement of 51Cr release.
Maximum release (MR) was obtained by treating target cells with
Figure 1. Cytokine profile of the CD4+ T helper clones derived from the intestinal mucosa of 8 patients with Behçet syndrome. Intestinal mucosa derived-T cell
clones were obtained from 8 patients with BD and from 10 HCs. Duplicate samples of supernatants of mitogen-stimulated T cell clones were assayed for cytokine
production. CD4+ clones able to produce IFN-g, but not IL-4, nor IL-17 were categorized as Th1, CD4+ clones able to produce IL-17, but not IL-4, nor IFN-g were
categorized as Th17, CD4+ clones producing both IFN-g and IL-17 were coded as Th1/Th17, CD4+ clones producing both IFN-g and IL-4 were coded as Th0, and
CD4+ clones able to produce IL-4, but not IFN-g, nor IL-17 were categorized as Th2. BD=Behçet disease, CD=cluster of differentiation, HC=healthy control,
IFN= interferon, IL= interleukin, Th=T helper.
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in microcultures without T cells. Specific lysis was calculated
according to the formula: Percent Specific Lysis=100 (Experi-
mental ReleaseSR)/(MRSR). Cultures in which 51Cr release
exceeded the mean SR by more than 5 SD were considered
positive for cytolytic activity.2.5. Fas–Fas ligand-mediated apoptotic killing
The ability of intestinal T-cell clones to induce Fas–Fas ligand-
mediated apoptosis was assessed using Fas+ Jurkat cells as
target.[22] T-cell blasts from each clone were cocultured with
51Cr-labeled Jurkat cells at an effector-to-target ratio of 10, 5,
and 2.5 to 1 for 18hours in the presence of PMA (10ng/mL) and
ionomycin (1mmol/L). Specific lysis was calculated according to
the formula reported above.2.6. Statistical analysis
Statistical comparison between groups was performed using the
Mann–Whitney U test or the Wilcoxon test, as appropriate.
Differences were considered as statistically significant when P<
0.05.Figure 2. Cytokine profile of the CD8+ T cell clones derived from the intestinal
mucosa of 8 patients with Behçet syndrome. Intestinal mucosa derived-T cell
clones were obtained from 8 patients with BD and from 10 HCs. Duplicate
samples of supernatants of mitogen-stimulated T cell clones were assayed for
cytokine production. CD8+ clones able to produce IFN-g, but not IL-4, were
categorized as Tc1, whereas CD8+ clones producing both IFN-g and IL-4 were
coded as Tc0, respectively. BD=Behçet disease, HC=healthy control, IL=
interleukin.3. Results
3.1. Predominance of Th1 and Th1/Th17 lymphocytes in
the intestinal mucosa
T-cell clones (n=382) were obtained from the intestinal mucosa
of 8 patients with BD in order to investigate their phenotype in
early phases of the disease: 324 were CD4+ and 58 were CD8+.
All intestinal-derived clones were analyzed for their cytokine
profile by measuring mitogen-induced production of IFN-g,
TNF-a, IL-4, and IL-17. In all BD patients, the majority (n=195)
of intestinal-derived clones were CD4 able to secrete IFN-g and
TNF-a but not IL-4, nor IL-17 thus showing a polarized Th1
profile (Fig. 1). CD4 clones producing IL-17, but not IFN-g nor
IL-4 were 21, whereas CD4 clones producing both IL-17 and
IFN-g (Th1/Th17 clones) were 79. CD4 clones able to secrete
both IFN-g and IL-4 (type 0 profile or Th0) accounted for only 29
clones. No clone from BD patients produced IL-4, but not IFN-g
nor IL-17 (Th2 clone). Likewise, in BD patients, the number of
CD8 clones producing type 1 cytokines (Tc1 clones) (n=50) was
higher than those (n=8) of CD8 clones producing both type 1
and 2 cytokines (Tc0 clones) (Fig. 2). From the intestinal mucosa
of healthy controls (HC) we isolated 311 CD4+ clones and 423CD8+ clones, respectively. Of note, all intestinal T-cell clones
produced high concentrations of TNF-a (Fig. 3), particularly
upon stimulation with PMA plus insoluble anti-CD3 antibody in
the absence of APCs (mean±SE, 5.2±0.7ng/mL per 106 T cells),
suggesting that high TNF-a production was a peculiar property
of intestinal T cells of patients with BD, because under the same
experimental conditions, in the series of intestinal T-cell clones
from 10 healthy controls TNF-a-producing clones were 78%,
with a mean (±SE) production of 1.3±0.6ng/mL per 106 T cells
(P<0.05). It is of note that in healthy control the number of
intestinal clones producing IFN-g and/or IL-17 was significantly
lower than in BD patients (P<0.05) (Fig. 1).
3.2. Intestinal T-cell clones can induce death in target
cells via both perforin- and Fas–Fas ligand-mediated
pathways
Because most activated Th1, Th17, and Th0 clones express
perforin-mediated cytotoxicity[23] the cytolytic potential of
intestinal T-cell clones from patients with BD and HC was
assessed by using PHA-pulsed 51Cr-labeled P815 as targets. At
the effector-to-target ratio of 10 to 1, 315/324 (97%) Th clones of
BD patients lysed target cells following PHA activation (Fig. 4A),
whereas 58% Th clones of HC were indeed cytolytic. Because
activated effector T cells can also kill their targets by inducing
apoptosis through Fas–Fas ligand interaction,[22] we evaluated
the ability of activated intestinal clones to induce 51Cr release by
Figure 3. TNF-a production of the CD4+ T cell clones derived from the
intestinal mucosa of patients with Behçet syndrome. Intestinal mucosa
derived-T cell clones obtained from 8 patients with BD produced significantly
(P<0.05) less TNF-a than those obtained from the 10 HCs. Duplicate samples
of supernatants of mitogen-stimulated T cell clones were assayed for TNF-a
production. BD=Behçet disease, HC=healthy control, IL= interleukin.
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247/324 (76.2%) Th clones of BD patients were able to induce
apoptosis in target cells (Fig. 4B) whereas 49% Th clones of HC
were able to induce apoptosis. The role of Fas–Fas ligand
interaction in this 51Cr release was confirmed by its inhibition
(>50%) by a blocking anti-Fas antibody.
4. Discussion
In the present study, we clearly showed that in the early stages of
active gut involvement of BD patients, cytotoxic Th1 and Th17
cells drive inflammation and that all the T cells at mucosal level
are able to produce large amount of TNF-a, thus potentially
leading to intestinal mucosal damage via different mechanisms.
Indeed, the intestinal manifestations of BD represent one of the
most important involvement of the disease in terms of morbidity
and mortality.[24] Ileocecal ulcers are the most common among
BD lesions, although any segment of intestinal tract could be
damaged. Behçet patients may complain mild (abdominal pain,
with or without diarrhea) to severe intestinal complications,Figure 4. Cytotoxic and proapoptotic activity of intestinal mucosa-derived T ce
cytotoxicity of Th clones derived from 8 patients with BD and from 10 HCs. To ass
were cocultured at 10/1 effector-to-target ratios with51Cr-labeled P815 cells pulsed
target cell lysis. (B) Percentage of fas ligand-mediated apoptosis of Th clones deriv
cells, intestinal mucosa-derived T cell clones were stimulated with mitogen or me
release was measured as index of apoptotic target cell death. BD=Behçet disea
4mainly including perforation with hemorrhage and fistula
formation.[24] Systemic corticosteroids and traditional immuno-
suppressants have been used,[25] but current evidence suggests
that anti-TNFa biological agents are effective in BD[26] and could
be useful as standard therapy for moderate to severe gastrointes-
tinal involvement of Behçet patients.[26] Indeed, the use of human
monoclonal antibody adalimumab has been recently approved in
Japan for the treatment of BD patients with intestinal involve-
ment.[27] In the past, some studies have indirectly shown the
production of TNF-a in patients with BD with intestinal
involvement, but without any specific data on the duration of
the disease.[13,14] Of note, in our study we have shown that all the
T cells infiltrating the intestinal mucosal of Behçet patients with
early symptoms (abdominal pain and/or diarrhea started within 6
months), both with or without intestinal ulcers at endoscopy
evaluation, are able to produce large amounts of TNF-a; this
evidence supports the use of anti-TNF-a treatment, such as
infliximab and adalimumab, also in the early stages of intestinal
involvement, thus preventing the onset of more serious
complications. Interestingly, it has been shown that anti-TNF-
a treatments are able to exert their effects also increasing the
proportion of Tregs, while inhibiting the differentiation of Th17
cells in Behçet patients with uveitis.[10,11] This observation is very
interesting in the light of our results; indeed anti-TNF-a could be
effective in the early phases of gut involvement of Behçet patients
due to both their direct capacity to inhibit the local production of
TNF-a, as well as for their ability of modulate the T cells balance.
To date a Th1, but not a Th17 phenotype has been described in
the gastrointestinal mucosa of BD patients.[13,14] Indeed, in 2005
Imamura observed by immunohistochemistry analysis that cells
infiltrating the intestinal lesions of Behçet patients were mainly
constituted by CD4+T lymphocytes. Moreover, they detected in
the intestinal lesions the upregulated expression of mRNA of IFN-
a, Txk (a Th1-specific transcription factor) and CCR5 (a Th1-
chemokine receptor), suggesting that a Th1 inflammation takes
important part in BD patients. They also described in the intestinal
mucosa of the sameBDpatients an increased expression ofMIP1b,
specific ligand for CCR5.[13] In 2010 Ferrante et al[14] have
confirmed the relevance of Th1 response at the intestinal level of
patients with BD. In particular, they observed at mucosal level thells from patients with Behçet syndrome. (A) Percentage of perforin-mediated
ess the perforin-mediated cytotoxicity, intestinal mucosa-derived T cell clones
with PHA or medium alone, and 51Cr release wasmeasured as index of specific
ed from BD patients or HC. To assess the ability to induce apoptosis in target
dium alone and were cocultured with 51Cr-labeled Fas+ Jurkat cells. The 51Cr
se, HC=healthy control, Th=T helper.
[5] D’Elios MM, Del Prete G. Th1/Th2 balance in human disease.
Emmi et al. Medicine (2016) 95:49 www.md-journal.comupregulation of mRNA for TNF-a, IFN-a, IL-12p35, and IL27; a
significant increase of Th1-related cytokines was also detected in
the peripheral bloodofBehçet patients.More recently, IL-17A, IL-
23R, and STAT4 polymorphisms were described in BD patients
with intestinal involvement, thus suggesting that also Th17 cells
may participate to the mechanisms finally leading to the organ
damage.[12] In our study, we observed at mucosal level a great
proportion of CD4+T cells; interestingly, these cells displayed a
polarized Th1 or a Th1/Th17 phenotype. These results indicate for
thefirst time that in early stagesof intestinal involvement, bothTh1
and Th17 cells drive inflammation in the intestinal mucosa of
patients with BD and suggest that blocking their inflammatory-
related cytokines might be useful for the treatment of the disease.
Interestingly, targeting the Th17-related cytokines pathways has
been proposed; a recent randomized control clinical trial
conducted in 118 patients failed to demonstrate the superiority
of the anti-IL17 secukinumab in the treatment of uveitis in Behçet
patients.[28] Nevertheless, blocking the IL17 axis could be
important in the treatment of organ involvement other than
ocular, and thus representing a novel promising treatment, at least
for some disease phenotypes, such as the intestinal ones.
Moreover, we have shown for the first time that the T cells
infiltrating the intestinal mucosa of Behçet patients are able to
induce death in target cells via both perforin- and Fas–Fas
Ligand-mediated pathways. Interestingly, a CD8brightCD56+ T
cells population with cytolytic potential have been demonstrated
in patients with active Behçet uveitis; these cells are able to exert
their harmful effects through both Fas ligand-dependent and
perforin-dependent pathways.[29] Thus, also at the early stages of
intestinal involvement, both CD4+ and CD8+ T cells are able to
express their potential cytolytic damage in BD patients, via both
perforin- and Fas–Fas ligand-mediated pathways.
The results obtained in this study indicate that in the early
stages of BD gut involvement, both Th1 and Th17 cells drive
inflammation. Moreover, those T cells, if inflammation proceeds
unabated, may lead to mucosal damage via abnormal and long-
lasting cytokine production as well as via both perforin- and
Fas–Fas ligand-mediated cytotoxicity. Finally, all the T cells at
mucosal level were able to produce large amount of TNF-a,
suggesting that its production is a peculiar property of intestinal T
cells of patients with early active intestinal disease. Overall the
results obtained support the therapeutic approach with anti-
TNF-a biological agents and suggest the possible use of anti-IL-
17 monoclonal antibodies in BD patients with early intestinal
involvement. This could allow to start an effective targeted
therapy in the early stages of the disease, thus preventing the most
severe and invalidating intestinal complications, such perforation
with hemorrhage and fistula formation.
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